γ-MSH (gamma-melanocyte-stimulating hormone): the MC3R-selective melanocortin

Even the system's edges do useful work — γ-MSH leaves colour and appetite to its siblings and keeps watch on the body's inner balance.

γ-MSH — gamma-melanocyte-stimulating hormone — is the melanocortin that refuses to fit the pattern. Most peptides in this family, led by α-MSH, are broad-spectrum signals that touch several receptors and headline in pigment and appetite. γ-MSH is comparatively picky about its receptor, and its main claim to fame is somewhere else entirely: the control of sodium and blood pressure.^[1]

Three peptides from the quiet end of POMC

POMC is cut into its hormones at pairs of basic amino acids, and the melanocortins come from three different stretches of it. α-MSH is carved from within ACTH in the middle; β-MSH from β-lipotropin at the C-terminal end; and γ-MSH from the N-terminal fragment, the part of the precursor that was for years regarded as biologically silent.^[3] Three versions exist, cut at different points of that fragment: γ1-MSH, an 11-residue amidated peptide; γ2-MSH, one residue longer; and γ3-MSH, a longer glycosylated form. All three carry the His-Phe-Arg-Trp core that defines the family, and the processing that releases them depends on prohormone convertase 2, the same enzyme that finishes α-MSH in the brain.^[3] The N-terminal fragment and its products are not quite silent at the adrenal, either: in 1982 Lowry's group showed that N-terminal POMC peptides stimulate adrenal cell division, and the longer γ3-MSH forms potentiate ACTH's steroidogenic effect — a supporting role to the receptor MC2R that γ-MSH itself cannot activate.^[10]

The receptor built for it

Where α-MSH activates four of the five receptors strongly, γ-MSH is relatively MC3R-preferring. The pairing is written into the receptor's history: when MC3R was cloned in 1993 the paper described it as a receptor for γ-melanotropin, because it was the first melanocortin receptor that responded well to γ-MSH, and it was found in the hypothalamus and limbic system rather than in skin or adrenal.^[2] Thirty years later the cryo-EM structure of MC3R bound to γ-MSH showed why: beyond the shared core, the peptide's C-terminal tail reaches into a groove specific to MC3R that α-MSH cannot use, while at the neighbouring MC5R the same tail barely makes contact.^[11] γ-MSH has only weak activity at MC1R, MC4R and MC5R and none at MC2R, so it drives little pigment or satiety signalling on its own — the activity grid is laid out in the binding matrix. That selectivity is exactly why MC3R and γ-MSH are discussed as a pair: the receptor's quieter, harder-to-pin-down physiology and its most selective ligand belong to the same story.

A job in salt

γ-MSH's distinctive role is in sodium balance. Infused into rats at doses that leave blood pressure and kidney blood flow unchanged, it increases sodium excretion — a natriuretic effect that does not run through the usual haemodynamic routes.^[4]The physiology behind it is a feedback loop. Eating more salt raises the pituitary's processing of POMC to γ-MSH and the level of γ-MSH in the blood; γ-MSH, through MC3R, drives sodium out; blood pressure stays normal.^[1] The decisive test was to break the loop. Mice lacking MC3R, and mice lacking prohormone convertase 2 and therefore unable to make γ-MSH, have normal blood pressure on an ordinary diet but become markedly hypertensive on a high-salt one. In the PC2-deficient animals, infusing γ-MSH brought the pressure back down; in the MC3R-deficient animals it could not, because the receptor was gone.^[5] A high-salt diet also raises MC3R abundance in the rat kidney, as if the system turns up both the signal and the receiver.^[6]

Where the receptor actually sits is less settled than the loop itself. The natural assumption was MC3R on kidney tubules, inhibiting sodium reabsorption directly. But a careful look found neither MC3R protein nor its messenger RNA in mouse kidney, and γ-MSH had no effect on sodium transport in collecting-duct cells, which points instead to MC3R in the nervous system acting on the nerves that control the kidney.^[7] The loop is real; the wiring diagram is still being drawn.

The pressor paradox

At the same time, γ-MSH can raise blood pressure. Injected directly into the brain of mice it increases blood pressure and heart rate by stimulating sympathetic outflow — but this is not an MC3R effect. It happens just as strongly in mice lacking MC3R, and it is abolished by benzamil, an amiloride analogue, which points to γ-MSH acting on an amiloride-sensitive sodium channel in the brain rather than on a melanocortin receptor. Central α-MSH raises pressure too, but through MC4R, the route the obesity drugs have had to contend with.^[8] So the same peptide lowers pressure through its receptor in the periphery and raises it through a non-receptor route in the brain. The two findings come from two different experiments — peptide infused into the circulation versus peptide injected into the ventricles — and the reviews that weigh them treat the salt loop as the physiological role and the central pressor effect as a pharmacological one whose relevance at natural concentrations is unproven.^[12]

Why there is no γ-MSH drug

The loop is a plausible drug target: salt-sensitive hypertension is common, and a stabilised γ-MSH analogue given to rats on a high-salt diet prevented the rise in blood pressure.^[9] Yet no γ-MSH-based medicine has entered the clinic. The reasons are the usual ones for a peptide hormone — short half-life, the difficulty of dosing a loop rather than a switch — plus the unresolved question of where MC3R acts and the knowledge that the peptide does the opposite thing centrally. MC3R has found its way into the pipeline by another door: dual MC3R/MC4R agonists for obesity, which exploit the receptor's role in energy partitioning rather than salt. γ-MSH's own pharmacology, meanwhile, remains an unusually clean piece of physiology waiting for a use.

The honest bottom line

γ-MSH is the family's specialist in the way ACTH is: it took the melanocortin chassis and pointed it at a different problem. It is a useful correction to the idea that these peptides are interchangeable — the receptor a melanocortin prefers, and the tissue it acts in, can change its job entirely — and a reminder that "melanocortin" names a family of related signals with genuinely different physiological work. For the receptor at the centre of γ-MSH's biology, see MC3R — energy partitioning.